Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. We performed an indirect treatment comparison of cemiplimab and othe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Future oncology (London, England) England), 2021-02, Vol.17 (5), p.611-627
Hauptverfasser:	Keeping, Sam, Xu, Yingxin, Chen, Chieh-I, Cope, Shannon, Mojebi, Ali, Kuznik, Andreas, Konidaris, Gerasimos, Ayers, Dieter, Sasane, Medha, Allen, Rachel, Huynh, Thi-Minh-Thao, Popoff, Evan, Freeman, Morganna, Andria, Michael L, Fury, Matthew G, Singh, Kanwarjit, Stockfleth, Eggert, Challapalli, Amarnath, Schmults, Chrysalyne D
Format:	Artikel
Sprache:	eng
Schlagworte:	cemiplimab cutaneous squamous cell carcinoma immuno-oncology indirect treatment comparison nonmelanoma skin cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!